FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.
What happened
FDA inspected Brassica Pharma's drug manufacturing facility from January 15 to 19, 2024. It found that the firm did not test every batch for sterility and fabricated sterility and environmental monitoring records. Four sterility tests during the inspection failed, including one U.S. product, and investigators saw 37 ISO 5 and 17 ISO 7 action-level environmental excursions plus poor aseptic practices, gowning, media fills, airflow, sterilization validation, facility pressure, and cleaning.
What FDA found
The firm did not test every batch for sterility and fabricated sterility and environmental monitoring records.
21 CFR 211.194(a)The firm did not follow adequate procedures to prevent microbial contamination and did not adequately validate aseptic and sterilization processes.
21 CFR 211.113(b)Aseptic processing areas and lines were not adequately designed or controlled to prevent contamination; pressure reversals and an insufficient environmental monitoring program were found.
21 CFR 211.42(c)(10)The firm did not adequately clean equipment that contacts sterile tubes and did not validate cleaning under routine conditions.
21 CFR 211.67(a) and 211.67(b)
What FDA wants
FDA asks Brassica to provide a comprehensive data-integrity investigation, patient-risk assessments, and global corrective action plans, plus independent assessments of its laboratory, aseptic processing and environmental monitoring. The letter does not state a response deadline.
Who should pay attention
- companies buying sterile ophthalmic or other finished drugs from this contract manufacturer
- brands relying on Brassica for U.S. sterile drug supply
- quality teams auditing sterile contract manufacturers and data integrity
This is a summary. Read the original letter on fda.gov.